Russell Investments Group Ltd. Makes New Investment in Kestra Medical Technologies, Ltd. $KMTS

Russell Investments Group Ltd. bought a new position in Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 18,343 shares of the company’s stock, valued at approximately $457,000.

Other large investors have also recently modified their holdings of the company. Virtu Financial LLC purchased a new position in shares of Kestra Medical Technologies in the first quarter worth about $210,000. Caas Capital Management LP purchased a new position in shares of Kestra Medical Technologies in the first quarter worth about $1,470,000. Jennison Associates LLC purchased a new position in shares of Kestra Medical Technologies in the first quarter worth about $1,869,000. TD Asset Management Inc purchased a new position in shares of Kestra Medical Technologies in the first quarter worth about $2,306,000. Finally, Invesco Ltd. purchased a new position in shares of Kestra Medical Technologies in the first quarter worth about $4,984,000.

Analyst Ratings Changes

Separately, Wells Fargo & Company reduced their target price on shares of Kestra Medical Technologies from $28.00 to $27.00 and set an “overweight” rating for the company in a research note on Thursday, July 17th. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $27.33.

Kestra Medical Technologies Stock Down 8.9%

Shares of NASDAQ:KMTS opened at $16.14 on Monday. The company’s 50 day moving average price is $16.23. Kestra Medical Technologies, Ltd. has a 12 month low of $13.25 and a 12 month high of $26.15. The company has a debt-to-equity ratio of 0.20, a current ratio of 6.72 and a quick ratio of 6.72.

Kestra Medical Technologies Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.